OliX Pharmaceuticals to Conduct One-on-One Meetings at BIO-Europe Digital 2021 Conference

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

SUWON, Republic of Korea, Oct. 21, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc .

Metadata
Provider: 
GlobeNewswire, Inc.GlobeNewswire, Inc.
Retrieved on: 
Thursday, October 21, 2021
Information
Tags: 
Korea, Head, Idiopathic pulmonary fibrosis, Technology, Hypertrophic scar, AMD, Institute of Liver and Biliary Sciences, Neuropathic pain, Hair loss, RNA interference, KOSDAQ, Hepatitis B virus, RNA, IPF, Fatty liver disease, NASH, Therapy, GLOBE, HBV, Disorder, Vaccine
Geotags: 
KR, SOUTH KOREA
Organisation: 
OLIX PHARMACEUTICALS
Summary
Key Points: 
  • SUWON, Republic of Korea, Oct. 21, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc .
  • (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Companys management will hold one-on-one partnering meetings at BIO-Europe Digital 2021, being held virtually October 25-28, 2021.
  • The Companys core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered the most efficient gene silencing technology.
  • OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.



SUWON, Republic of Korea, Oct. 21, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will hold one-on-one partnering meetings at BIO-Europe Digital 2021, being held virtually October 25-28, 2021.

Sun Woo Hong, Ph.D., head of R&D at OliX Pharmaceuticals, and June Hyun Park, Ph.D., principal scientist at OliX Pharmaceuticals, will be available to discuss platform-based early discovery collaborations as well as global licensing options for the Company’s pipeline programs for OLX703A for hepatitis B virus (HBV), OLX104C for androgenic alopecia (hair loss) and OLX702A for non-alcoholic steatohepatitis (NASH).

To schedule a virtual meeting, please visit the BIO-Europe partneringONE® platform here: https://informaconnect.com/bioeurope/partnering/

About OliX Pharmaceuticals

OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered the most efficient gene silencing technology. Utilizing this proprietary asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target diseases locally, such as hypertrophic scarring, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, idiopathic pulmonary fibrosis (IPF), and neuropathic pain. OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

Learn more: https://www.olixpharma.com/eng/

Media Contact:

Jon Yu
ICR Westwicke PR
Phone: +1.475.395.5375
[email protected]  


Primary Logo
Copyright: 
2021 GlobeNewswire, Inc.. All Rights Reserved.